Interesting research from Stanford University, California, on the switching on and off of Transglutaminase 2 (TG2). Researchers identified an enzyme that turns off TG2 which could lead to future treatments for celiac disease.
(2.23.18) Stanford University study findings were published in American Society for Biochemistry and Molecular Biology ‘s Journal of Biological Chemistry
(from article published on phys.org) “Celiac disease is an autoimmune disorder that affects by some estimates nearly 1 in 100 people. Celiac disease symptoms are triggered by gluten, a protein found in wheat and related plants, but gluten doesn’t act alone to cause the digestive symptoms that patients suffer. Rather, gluten induces an overactive immune response when it’s modified by the enzyme transglutaminase 2, or TG2, in the small intestine. New research published in the Feb. 23 issue of the Journal of Biological Chemistry identifies an enzyme that turns off TG2, potentially paving the way for new treatments for celiac disease.” Read more at: https://phys.org/news/2018-02-celiac-disease.html#jCp
View study abstract here
